Deutsche Bank AG Invests $4.14 Million in Celcuity, Inc. $CELC

Key Points

• Deutsche Bank acquired 39,622 Celcuity shares worth approximately $4.14 million in the second quarter, while institutional investors and hedge funds collectively owned 63.33% of the company.
• Analyst sentiment remains positive, with 10 analysts rating CELC a Buy and one assigning a Sell rating. The stock has a consensus “Moderate Buy” rating and an average price target of $154.55.
• Celcuity shares opened at $92.27, well below their 12-month high of $151.02. The company reported a quarterly loss of $1.44 per share, missing estimates by $0.28, and analysts expect a full-year loss of $4.51 per share.

Deutsche Bank AG acquired a new position in Celcuity, Inc. (NASDAQ:CELC - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 39,622 shares of the company's stock, valued at approximately $4,145,000. Deutsche Bank AG owned approximately 0.08% of Celcuity at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its position in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock worth $34,000 after acquiring an additional 319 shares during the period. US Bancorp DE increased its holdings in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after purchasing an additional 143 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after purchasing an additional 1,167 shares during the period. Parallel Advisors LLC bought a new stake in shares of Celcuity during the first quarter valued at about $38,000. Finally, Meeder Asset Management Inc. acquired a new stake in Celcuity in the fourth quarter worth about $42,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CELC. Citizens Jmp reiterated a "market outperform" rating and issued a $177.00 target price on shares of Celcuity in a research report on Monday, August 17th. Guggenheim boosted their price target on shares of Celcuity from $165.00 to $175.00 and gave the stock a "buy" rating in a research report on Monday, August 17th. Leerink Partners set a $155.00 price target on shares of Celcuity in a research note on Tuesday, June 2nd. Needham & Company LLC decreased their price objective on shares of Celcuity from $157.00 to $140.00 and set a "buy" rating for the company in a report on Friday, August 14th. Finally, Macquarie Infrastructure set a $160.00 price objective on shares of Celcuity in a research note on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Celcuity currently has a consensus rating of "Moderate Buy" and an average price target of $154.55.

Celcuity Stock Performance

Shares of CELC opened at $92.27 on Wednesday. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. The firm's 50 day moving average is $94.38 and its 200-day moving average is $107.44. Celcuity, Inc. has a 12-month low of $44.42 and a 12-month high of $151.02. The stock has a market capitalization of $4.51 billion, a P/E ratio of -21.46 and a beta of 0.20.

Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Equities research analysts anticipate that Celcuity, Inc. will post -4.51 EPS for the current fiscal year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source